Tenvie Therapeutics, TNV313, NLRP3 inhibitor, Phase 1 clinical trial, central nervous system, CNS penetration, neuroinflammation, neurological diseases, cardiometabolic disease

BRISBANE, Calif. — October 13, 2026 Tenvie Therapeutics, a clinical-stage biotechnology company developing precision-engineered small-molecule therapies for neurological and...